Moira brings over 15 years’ experience in the healthcare industry developing new products from both the scientific and commercial side. At Evidera, she assists with health technologies with significant disruptive potential such as personalized medicine, diagnostics, orphan drugs, combination products, e- technologies, cell therapy and regenerative medicine, immuno-oncology and vaccines, and e-connectivity technologies.
Moira is experienced in enhancing value propositions for emerging healthcare technologies. Prior to Evidera, she developed patient, physician and payer strategies for a specialty pharmaceutical manufacturer applying novel drug delivery technology to neurology and orphan disease indications. She has formulated stakeholder value demonstration and business strategies for innovative pipeline biopharma products in the U.S., Europe, and emerging markets as Design to Value Lead at GlaxoSmithKline. She is an expert at understanding and addressing patient adherence from a cultural, psychological, and product design perspective. Moira also has corporate strategy and financial valuation experience in developing of academic, commercial, and social venture partnerships for commercial and R&D innovation groups.
Prior to these roles, she managed a scientific team at GlaxoSmithKline R&D and helped develop over ten pharmaceutical products spanning pre-clinical to post-approval. Her scientific contributions resulted in five approved drug products in the U.S., Europe, and Japan spanning neurology, oncology, and urology.
Moira is a graduate of the Duke Fuqua School of Business, with an MBA in health sector management. She also holds a PhD from the University of Michigan in chemistry.